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INTRODUCTION
Since Helicobacter pylori (H. pylori) is
the first successful culture three decades
ago, ongoing perspectives regarding the
relationship between the bacterium and
human health have changed radically (1, 2).
Apart from tremendous studies performed
during the last years, there are still many
debates regarding the unclear rationale for
existence of such bacteria in human stom-
ach (3, 4). Basically, due to the beneficiary
effects of H. pylori colonization (regression
in child asthma and other allergic disor-
ders), it has been concluded that H. pylori
is a common flora or at least harmless
bacterium (5–10), Conversely, because of
the causative role of H. pylori in certain
digestive diseases such as duodenal ulcer
and gastric cancer, other reports are quite
contradictory (11–13). A large number of
discussions led to a consensus regarding
presence of H. pylori in the human stomach
(5, 11, 14, 15). Our knowledge about biol-
ogy of H. pylori suggests that the bacterium
is highly adapted to stay in gastric mucosa
for long time (1, 16). Indeed, living in lower
surface of gastric mucosa, with no bacte-
rial competition, provided a novel place
to survive. Moreover, H. pylori is able to
multiply freely due to the protective effects
by mucosal layer. Thus, H. pylori had an
opportunity to thrive in stomach over the
course of tens of thousands of years of
co-evolution with humans (17). Addition-
ally, the high frequency of mutation in the
genome also led to higher chances of sur-
vival, and natural selection helped them to
remain and cause chronic infection (18).
Determining whether H. pylori is benefi-
cial or detrimental in human stomach has
been a challenging area of research in gas-
troenterology (5, 11, 19, 20). In this article,
we aim to elucidate various aspects of this
persistent colonization of this beneficial
infection.
H. PYLORI : CARRIED BY HUMAN OVER THE
HISTORY
It seems that H. pylori is an old recognized
bacterium, which is not clinically compara-
ble with new discovered infectious agents
such as human immunodeficiency virus
(HIV). In other words, HIV was intro-
duced to human hosts <50 years ago. Given
a long period of H. pylori colonization
in the human stomach, mutual benefits
obliged both partners to adapt themselves
in order to establish stable symbiosis. It
has been firmly established that H. pylori
first subverts innate immunity and then
modulates the adaptive immune system
(blocking the activation of both B and T
cells) (21–23). As a result, cagA and vacA,
the main bacterial products, will inhibit
B cell and T cell proliferation, respec-
tively. Accordingly, immune response in
the stomach is silenced against digested
microbes (24, 25). Undeniably, the stom-
ach, with its harsh acidic condition, is
a container for many digested microbes
every day. Possibly, regulation and mod-
ulation of immune response arose after
microbial exposure to H. pylori coloniz-
ing the stomach (24, 25). Our current
understanding of the strategies used by this
pathogen to make a lifelong colonization,
disclosed that maybe for our old ances-
tors having this bacteria in the stomach
happened initially by accident, but due
to natural selection, H. pylori made a set
of adaptations, enabling the bacterium to
survive and also thrive in the surface of
human gastric epithelial cells. To every-
one’s surprise, after millions years of liv-
ing in human stomach, H. pylori became
a strategic member of our microbiome
(26). Undoubtedly, it is no exaggeration
to say that both host and the bacterium
are following a constant beneficial relation-
ship, which is quite unique in biological
world. After long period of H. pylori gastric
colonization, it has evolved into a highly
adaptable persistent bacterium, obtaining
all necessary features of the most successful
human pathogen.
GERD AND H. PYLORI : A GOOD EXAMPLE OF
BENEFICIAL EFFECTS
Gastroesophageal reflux disease (GERD)
incidence has been increased mostly in
developed communities where H. pylori
infection is almost effectively eradicated
(27, 28). GERD is the main risk factor
for Barrett’s esophagus, and it has been
associated with another deadly gastroduo-
denal carcinoma called “esophageal ade-
nocarcinoma” (3, 5). However, the rela-
tionship between GERD and H. pylori
remains incompletely defined (29). Sev-
eral studies suggested that eradication of
H. pylori infection in the setting of duo-
denal ulcer disease would result in an
increase in GERD symptoms (3, 30). In
other words, an inverse association of H.
pylori infection with decreased rate of this
sort of disease was a challenging topic
in new gastroenterology (14, 31–33). Of
note, GERD and its sequelae, which include
Barrett’s esophagus and esophageal ade-
nocarcinoma, is decreasing in countries
in which most individuals are infected
by H. pylori (15, 34, 35). Actually, not
only has worldwide H. pylori prevalence
changed in recent decades but also other
environmental factors affecting on human
health such as socioeconomical levels, diet,
and vaccination were drastically changed
(10, 17). If so, H. pylori is confronting
with different situation rather than before.
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Remarkably, H. pylori can undergo dras-
tic genetic change through each genera-
tion, while human genes do not change
frequently. As a result, frequent genetic
changes in H. pylori helped the bacterium
to adapt quickly (18). Remarkably, slower
adaptation in humans deteriorates long-
time established equilibrium between H.
pylori and human. Because of this, elim-
ination of H. pylori as permanent resi-
dent of human microbiome would not be
the first option to deal with gastroduode-
nal diseases. According to what explained
about GERD and H. pylori as a protec-
tive effect, the long cohabitation in our
stomach calls for more deep studies to
elucidate microbiota and human health.
GERD is the best example of disease, which
became more frequent after starting the
H. pylori treatment (34). Indeed, after
antibiotic usage against H. pylori and, of
course, its eradication in Western countries,
a constant equilibrium between H. pylori
and human health disappeared. Interest-
ingly, in Northeastern Malaysia, the low
prevalence of H. pylori infection was fre-
quently reported (36–38). As general rule,
one expects that frequency of diseases such
as asthma and GERD should be relatively
low rather than the findings of expected
inverse association were not found (39–
41). Actually, the association between H.
pylori infection and certain diseases such
as GERD and asthma risk can be affected
by geographical and genetic differences (37,
41). As a result, there is a complex and
mostly undetermined associations between
human microbiome and health; accord-
ingly, all attempts to change this arranged
biological system can exacerbate certain
diseases. Undoubtedly, we need to eradicate
virulent H. pylori in people with adverse
clinical manifestations, but this conclu-
sion cannot be generalized to all H. pylori
positive subjects.
FUTURE OF H. PYLORI
The interesting relation between H. pylori
and humans has shown that gastric
acidic condition and human immune
responses, which resulted in highly adapt-
able microbe. Currently, half of the world
population is carrying strains that can
survive and multiply in human gastric
mucosa. Nowadays, available data about
microbiota are sharply increasing; hence,
one can expect to elucidate more details
about this mysterious part of our bod-
ies. In fact, experiments, which determine
an actual association between H. pylori
and microbiota, can increase our knowl-
edge regarding this persistent resident of
our stomach. Strikingly, both approaches,
(i) bacterial eradication for asymptomatic
individuals and (ii) global vaccination pro-
grams do not seem necessary in current
clinical setting. Alternatively, we can sug-
gest to only eradicating H. pylori in patients
with adverse clinical presentations. In the
end, with continuing current approach
against H. pylori, we will lose this old
ancient member of our microbiota; an
event, which we are not fully aware of its
drawbacks.
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